Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 20, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 30, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-030571
Filed / recorded
Jan 30, 2026, 1:30 PM UTC
Added to OQRO
Oct 8, 2026, 2:22 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ATOSSA THERAPEUTICS, INC.
Issuer CIK
1488039
Ticker
ATOS
Reporting person
Steven C Quay
Relationship
Director, Officer
Officer title
President & CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 20, 2026
Transaction code
A
Shares / units
331,674
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
345,572
Ownership form
Direct
Amendment
Yes (Form 4/A)
Footnotes from the filing
Represents the acquisition of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date.
The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.